Patents by Inventor Mark Cobbold
Mark Cobbold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10287321Abstract: The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.Type: GrantFiled: December 16, 2015Date of Patent: May 14, 2019Assignee: The University of BirminghamInventors: Mark Cobbold, David Millar
-
Publication number: 20190015494Abstract: Provided are compositions that include one or more peptides, wherein each peptide is at least 8 amino acids long and has an amino acid sequence as set forth in any of SEQ ID NOs: 1-45. Also provided are in vitro populations of dendritic cells that include the disclosed compositions, in vitro populations of CD8+ T cells capable of being activated upon being brought into contact with the disclosed populations of dendritic cells, antibodies or antibody-like molecules that specifically bind to complexes of MHC class I molecules and the disclosed peptides, methods for treating and/or preventing cancer such as leukemia using the disclosed compositions and/or populations, methods for making cancer vaccines using the disclosed compositions, methods for screening target peptides for inclusion in an immunotherapy composition, methods for determining a prognosis of a leukemia patient, and kits that include at least one of the disclosed peptides.Type: ApplicationFiled: August 5, 2016Publication date: January 17, 2019Applicants: University of Virginia Patent Foundation, The University of BirminghamInventors: Donald F. Hunt, Jeffrey Shabanowitz, Stacy Alyse Malaker, Mark Cobbold, Sarah Penny
-
Publication number: 20180346568Abstract: A targeted T-cell engaging agent for treating a condition characterized by the presence of unwanted cells includes (a) a targeting moiety that is capable of targeting the unwanted cells; (b) a first T-cell engaging domain capable of T-cell engaging activity when binding a second T-cell engaging domain, wherein the second T-cell engaging domain is not part of the agent; (c) at least one inert binding partner capable of binding to the first T-cell engaging domain such that the first T-cell engaging domain does not bind to the second T-cell engaging domain unless the inert binding partner is removed; and (d) at least one cleavage site separating the first T-cell engaging domain and the inert binding partner, wherein the cleavage site is: (i) cleaved by an enzyme expressed by the unwanted cells; (ii) cleaved through a pH-sensitive cleavage reaction inside the unwanted cell; (iii) cleaved by a complement-dependent cleavage reaction; or (iv) cleaved by a protease that is colocalized to the unwanted cell by a targetType: ApplicationFiled: June 28, 2018Publication date: December 6, 2018Applicant: Revitope LimitedInventor: Mark COBBOLD
-
Patent number: 10106621Abstract: The invention provides molecule comprising: (i) a targeting moiety capable of directly or indirectly targeting to unwanted cells, and (ii) a further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety to an immune cell, wherein the masked immune cell binding region is capable of being selectively unmasked when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an immune cell.Type: GrantFiled: September 19, 2017Date of Patent: October 23, 2018Assignee: The University of BirminghamInventors: Mark Cobbold, David Millar
-
Patent number: 10035856Abstract: A targeted T-cell engaging agent for treating a condition characterized by the presence of unwanted cells includes (a) a targeting moiety that is capable of targeting the unwanted cells; (b) a first T-cell engaging domain capable of T-cell engaging activity when binding a second T-cell engaging domain, wherein the second T-cell engaging domain is not part of the agent; (c) at least one inert binding partner capable of binding to the first T-cell engaging domain such that the first T-cell engaging domain does not bind to the second T-cell engaging domain unless the inert binding partner is removed; and (d) at least one cleavage site separating the first T-cell engaging domain and the inert binding partner, wherein the cleavage site is: (i) cleaved by an enzyme expressed by the unwanted cells; (ii) cleaved through a pH-sensitive cleavage reaction inside the unwanted cell; (iii) cleaved by a complement-dependent cleavage reaction; or (iv) cleaved by a protease that is colocalized to the unwanted cell by a targetType: GrantFiled: November 18, 2016Date of Patent: July 31, 2018Assignee: Revitope LimitedInventor: Mark Cobbold
-
Publication number: 20180105599Abstract: The invention provides molecule comprising: (i) a targeting moiety capable of directly or indirectly targeting to unwanted cells, and (ii) a further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety to an immune cell, wherein the masked immune cell binding region is capable of being selectively unmasked when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an immune cell.Type: ApplicationFiled: September 19, 2017Publication date: April 19, 2018Applicant: The University of BirminghamInventors: Mark COBBOLD, David MILLAR
-
Publication number: 20180066017Abstract: A set of phosphorylated peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive T-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical pathology samples, and (d) act as biomarkers for early detection of the disease. Phosphorylated peptides are also presented for other cancers.Type: ApplicationFiled: April 10, 2017Publication date: March 8, 2018Inventors: Donald F. Hunt, Jeffrey Shabanowitz, Jennifer Cottine, Ann M. English, Andrew Norris, Victor H. Engelhard, Mark Cobbold, Kara L. Cummings, Angela Zarling, Rebecca C. Obeng, Jie Qian
-
Publication number: 20170333541Abstract: A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.Type: ApplicationFiled: December 22, 2016Publication date: November 23, 2017Inventors: Donald F. Hunt, Jeffrey Shabanowitz, Stacy Alyse Malaker, Victor H. Engelhard, Angela Zarling, Kara L. Cummings, Rebecca C. Obeng, Mark Cobbold
-
Patent number: 9822180Abstract: The invention provides molecule comprising: (i) a targeting moiety capable of directly or indirectly targeting to unwanted cells, and (ii) a further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety to an immune cell, wherein the masked immune cell binding region is capable of being selectively unmasked when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an immune cell.Type: GrantFiled: February 28, 2013Date of Patent: November 21, 2017Assignee: THE UNIVERSITY OF BIRMINGHAMInventors: Mark Cobbold, David Millar
-
Publication number: 20170152316Abstract: A targeted T-cell engaging agent for treating a condition characterized by the presence of unwanted cells includes (a) a targeting moiety that is capable of targeting the unwanted cells; (b) a first T-cell engaging domain capable of T-cell engaging activity when binding a second T-cell engaging domain, wherein the second T-cell engaging domain is not part of the agent; (c) at least one inert binding partner capable of binding to the first T-cell engaging domain such that the first T-cell engaging domain does not bind to the second T-cell engaging domain unless the inert binding partner is removed; and (d) at least one cleavage site separating the first T-cell engaging domain and the inert binding partner, wherein the cleavage site is: (i) cleaved by an enzyme expressed by the unwanted cells; (ii) cleaved through a pH-sensitive cleavage reaction inside the unwanted cell; (iii) cleaved by a complement-dependent cleavage reaction; or (iv) cleaved by a protease that is colocalized to the unwanted cell by a targetType: ApplicationFiled: November 18, 2016Publication date: June 1, 2017Applicant: Revitope LimitedInventor: Mark COBBOLD
-
Patent number: 9650445Abstract: The invention provides molecule comprising: (i) a targeting moiety capable of directly or indirectly targeting to unwanted cells, and (ii) a further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety to an immune cell, wherein the masked immune cell binding region is capable of being selectively unmasked when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an immune cell.Type: GrantFiled: October 21, 2015Date of Patent: May 16, 2017Assignee: The University of BirminghamInventors: Mark Cobbold, David Millar
-
Patent number: 9561266Abstract: A set of target peptides are presented by HLA A*0101, A*0201, A*0301, B*4402, B*2705, B*1402, and B*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.Type: GrantFiled: September 3, 2013Date of Patent: February 7, 2017Assignees: University of Virginia Patent Foundation, The University of BirminghamInventors: Donald F. Hunt, Jeffrey Shabanowitz, Stacy A. Malaker, Victor H. Engelhard, Angela Zarling, Kara L. Cummings, Rebecca C. Obeng, Mark Cobbold
-
Publication number: 20160220665Abstract: A variety of targeting moiety peptide epitope complexes (TPECs) are described in different embodiments. In each of the embodiments, however, a targeting moiety may be used to deliver the TPEC to an area of unwanted cells, allowing for a therapeutic effect to be delivered locally. The TPEC also contains a plurality of T-cell epitopes. The TPEC further comprises cleavage sites that release the T-cell epitopes from the targeting agent, and in some embodiments from each other, when they are in the microenvironment of the unwanted cells. Although the arrangement and number of T-cell epitopes varies in different embodiments described herein, once cleaved from the targeting agent (and any neighboring T-cell epitopes), the T-cell epitopes function by stimulating an immune response against the unwanted cells.Type: ApplicationFiled: February 1, 2016Publication date: August 4, 2016Applicant: The University of BirminghamInventors: Mark Cobbold, David Millar
-
Patent number: 9402916Abstract: The invention provides an agent for preventing or treating a condition characterized by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.Type: GrantFiled: March 15, 2012Date of Patent: August 2, 2016Assignee: THE UNIVERSITY OF BIRMINGHAMInventors: Mark Cobbold, David Millar
-
Publication number: 20160206726Abstract: The invention provides an agent comprising: a cyclic peptide comprising a T cell antigen peptide; wherein in cyclised form the T cell antigen peptide is not capable of eliciting a T cell response; and wherein the T cell antigen peptide is rendered capable of eliciting a T cell response by selective cleavage of one or more cleavage sites in the cyclic peptide. The agent may be used to prevent or treat a condition characterised by the presence of unwanted cells.Type: ApplicationFiled: December 31, 2015Publication date: July 21, 2016Applicant: The University of BirminghamInventors: Mark Cobbold, David Millar
-
Patent number: 9358282Abstract: The invention provides an agent for preventing or treating a condition characterized by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.Type: GrantFiled: March 17, 2015Date of Patent: June 7, 2016Assignee: The University of BirminghamInventors: Mark Cobbold, David Millar
-
Publication number: 20160106862Abstract: The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising: (i) a targeting moiety that is capable of targeting to the unwanted cells; and (ii) a T cell antigen, wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.Type: ApplicationFiled: December 16, 2015Publication date: April 21, 2016Applicant: The University of BirminghamInventors: Mark Cobbold, David Millar
-
Publication number: 20160039942Abstract: The invention provides molecule comprising: (i) a targeting moiety capable of directly or indirectly targeting to unwanted cells, and (ii) a further moiety that has a masked immune cell binding region so as to prevent binding of the further moiety to an immune cell, wherein the masked immune cell binding region is capable of being selectively unmasked when the molecule is in the vicinity of the unwanted cells so as to allow binding of the further moiety to an immune cell.Type: ApplicationFiled: October 21, 2015Publication date: February 11, 2016Inventors: Mark Cobbold, David Millar
-
Publication number: 20150328297Abstract: A set of target peptides are presented by HLA A*0201, B*0301, B*0702 and B*2705 on the surface of disease cells. They are envisioned to, among other things, stimulate an immune response to the proliferative disease, e.g., colorectal cancer, to function as immunotherapeutics in adoptive T cell therapy or as a vaccine, facilitate antibody recognition of tumor boundaries in surgical pathology samples, act as biomarkers for early detection and/or diagnosis of the disease, and/or act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.Type: ApplicationFiled: September 5, 2013Publication date: November 19, 2015Inventors: Donald F. Hunt, Jeffrey Shabanowitz, Jennifer G. Abelin, Mark Cobbold, Sarah Amy Penny
-
Publication number: 20150297745Abstract: The invention provides an agent comprising: (i) a T cell antigen, and (ii) a binding partner for any of CD22, CD23, CD30, CD74, CD70, CD43, CD44, CD47, CD54, CD58, CD62L, CD95, HLA-DR, CD59, CD55, wherein, following binding of the agent to a cell that expresses any of CD22, CD23, CD30, CD74, CD70, CD43, CD44, CD47, CD54, CD58, CD62L, CD95, HLA-DR, CD59, CD55, the agent is internalised and the T cell antigen is presented on the surface of the cell in a form that can be recognised by a T cell.Type: ApplicationFiled: September 17, 2013Publication date: October 22, 2015Applicant: University of BirminghamInventors: Mark Cobbold, David Millar